THE GLOBAL DRUG-COATED BALLOONS MARKET SIZE TO BE VALUED AT USD 1.5 BILLION BY 2025, GROWING AT A CAGR OF 15% DURING 2020-2025

Drug-coated Balloons Market Size, Share, Trends Analysis Report by Indication (PAD, CAD, and Others), Drug Type (Paclitaxel and Sirolimus), End-user (Hospitals, Ambulatory Care Settings, and Freestanding Cath Labs), and Geography (APAC, North America, Europe, Latin America, and the Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Share & Forecast, 2020–2025

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

263 Pages

icon-table

51 Tables

icon-chart

120 Charts

icon-region

5 Regions

icon-country

19 Countries

icon-company

28 Companies

icon-market

4 Market Segment

DRUG-COATED BALLOONS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 1.5 BILLION (2025)
CAGR 15% (2020–2025)
Base Year 2019
Forecast Year 2020–2025
Market Segments Indication (PAD, CAD, and Others), Drug Type (Paclitaxel and Sirolimus), End-user (Hospitals, Ambulatory Care Settings, and Freestanding Cath Labs)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Argentina, Turkey, South Africa, Israel, and Saudi Arabia

INDUSTRY INSIGHTS

The global drug-coated balloons market size to cross USD 1.5 billion by 2025, growing at a CAGR of 15% during the forecast period. The global drug-coated balloons market is one of the fastest-growing segments in the cardiovascular devices market. The market is growing significantly due to the surge in incidence/prevalence of cardiovascular diseases, especially peripheral artery and coronary artery diseases across the globe.

Cardiovascular diseases are characterized by coronary artery disease (CAD) and peripheral artery disease (PAD). PAD is the third leading cause of atherosclerotic vascular morbidity, which affects approximately 200 million people worldwide. Besides, about 3.8 million men and 3.4 million women die from CAD per year. DCB technology is highly innovative and expected to influence the existing treatment modalities of vascular diseases and ESRD to a great extent. The introduction of DCBs has been a significant breakthrough in the cardiovascular industry with great high potential in terms of minimizing restenosis.

The COVID-19 pandemic is likely to profoundly affect the drug-coated balloons market in several countries across the globe. With the spread of the pandemic, several hospitals, CATH labs, and ASCs have experienced a rapid decline in the volume of elective cardiology procedures. Although COVID-19 is a global pandemic, some countries have experienced a higher incidence of the virus than others.

SNIPPETS

  • The increasing preference for percutaneous procedures with DCBs due to promising outcomes is one of the key driving factors for the global market.
  • North America will witness the highest growth rate over the forecast period, with over 16% globally.
  • The increasing focus on clinical trial outcomes is a significant factor for the global drug-coated balloons market.
  • The ASCs end-user segment is projected to grow at the highest CAGR of over 16% during the forecast period.

GLOBAL DRUG-COATED BALLOONS MARKET SEGMENTATION 

This research report includes a detailed segmentation by
  • Indication
  • Drug Type
  • End-user
  • Geography

INSIGHTS BY INDICATION

The peripheral artery disease (PAD) segment accounted for a share of over 81% in 2019, and it is expected to retain its market dominance during the forecast period. The adoption of drug-coated balloons (DCB) for treating PAD is growing rapidly, primarily due to the availability of positive clinical data, supporting the safety and efficacy of DCB technology. The segment accounts for the largest share as the majority of DCB devices are commercially available for PAD indication. However, despite high potential growth opportunities for treating PAD, the recent COVID-19 pandemic has caused unprecedented challenges to perform PCI procedures. The spread of the virus has triggered disruption across the globe with lockdowns, travel bans, and ban on large gatherings such as major cardiac scientific society meetings being canceled, with substantial pressure on the health care services across the world.

In 2019, the coronary artery disease (CAD) segment constituted over 11% of the global drug-coated balloons market. The market is growing at a significant rate and is likely to grow during the forecast period. The growth in the CAD patient pool globally is a major key factor for the growth of the segment. Cardiovascular diseases, especially CAD, are recognized as the leading cause of death globally. Moreover, a high prevalence of CAD in developing countries such as India, a significant health challenge, is likely to influence the segment growth.

INSIGHTS BY DRUG TYPE

The paclitaxel segment accounts for the maximum market share as these devices are safe and effective in treating CVDs, AV, and urological disorders. Paclitaxel-coated balloon (PCB) technology has emerged as a promising therapeutic alternative in the PCI procedure, especially for CVDs. The majority of commercially available DCBs are paclitaxel-coated. Paclitaxel-coated balloons are clinically proven, reducing the risk of restenosis after angioplasty of atherosclerotic femoropopliteal lesions. This is increasing their demand among healthcare professionals. In 2019, the sirolimus segment accounted for over 3% of the market. This segment is a new generation of DCBs, where balloons are coated with a medicine called sirolimus. There are a few commercially available sirolimus DCBs. Thus the contribution of the segment is low than paclitaxel-coated balloons.

INSIGHTS BY END-USER

The global drug-coated balloons market is segmented into hospitals, freestanding CATH labs, and ASCs. Healthcare professionals in hospitals use DCBs mainly for cardiovascular disorders, including AV interventions, urological, and neurovascular procedures. The segment is growing at a healthy rate due to the high adoption of the latest generation DCBs. A majority of patients with an increased risk of cardiovascular diseases prefer visiting hospitals for treatment due to advanced infrastructure facilities available in major private and public hospitals, the segment is expected to grow significantly.

In 2019, the freestanding CATH labs' end-user segment accounted for over 28% share. Freestanding CATH labs offer several advantages for patients that need endovascular procedures and significant financial benefits to health care professionals. Europe and France have the highest number of freestanding CATH labs, with around 2.9 freestanding CATH labs per one million. The presence of favorable reimbursement procedures is an essential factor contributing to the segment growth. These labs use cutting edge technology to perform several heart procedures. Continued technological innovations are helping freestanding CATH labs to perform minimally invasive procedures, which is increasing their market revenue.

INSIGHTS BY GEOGRAPHY

North America occupies a dominant position in the global drug-coated balloons market. The presence of a large disease population, coupled with better access to treatment, is the primary factor for the high market share. The market in North America is expected to witness lucrative growth during the forecast period due to expanded indication approvals for commercialized DCBs, new product approvals, and the availability of abundant clinical evidence.
 
The outcome from several clinical trials conducted in North America, especially in the US, is promising and encouraging physicians to use DCBs for treating various arterial diseases. The adoption of DCBs is likely to increase due to the future availability of positive clinical data, supporting the safety and efficacy of DCB technology in the region. The rise in the number of CVD, ESRD patient pool, and the necessity to treat the disease with endovascular procedures boost the market growth during the forecast period. 

INSIGHTS BY VENDORS

The global drug-coated balloons market is highly dynamic with the presence of global, regional, and local players offering a broad range of latest-generation DCBs for end-users. Medtronic, BD, Koninklijke Philips, Boston Scientific, and B. Braun Melsungen are the key vendors in the market in terms of technology, safety features, regulatory approvals, marketing strategies, and distribution channels.
 
These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovation, strategic mergers & acquisitions, and research activities. Vendors, especially global players, are increasingly focusing on pursuing inorganic growth strategies such as acquisitions and investments in startup and emerging companies to expand their presence, enhance product portfolio, and improve expertise in the industry.

The drug-coated balloons market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Indication
  • PAD
  • CAD
  • Others
By Drug Type
  • Paclitaxel
  • Sirolimus 
By End-user
  • Hospitals
  • Ambulatory Care Settings
  • Freestanding Cath Labs
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • Turkey
    • South Africa
    • Israel

Frequently Asked Questions

What is the global drug-coated balloons market size and growth rate during the forecast period?

The global drug-coated balloons market is expected to reach USD 1.5 Billion by 2025, growing at a CAGR of close to 16%.

What are the factors impacting the growth of the drug-coated balloons market share?

Factors such as promising outcomes of drug-coated balloons, increasing focus on investigational drug-coated balloons, and growing application of DCBs are major factors influencing the market growth

What is the growth of North America drug-coated balloons market during the forecast period?

North America is expected to witness the highest growth rate over the forecast period with over 16% in the global market.

Who are the leading vendors in the drug-coated balloons market?

Hillrom, Medtronic, BD, Koninklijke Philips, Boston Scientific, and B. Braun Melsungen are the key vendors in the market in terms of technology, safety features, regulatory approvals, marketing strategies, and distribution channels.

What is the impact of COVID-19 pandemic on the global market?

With the spread of the COVID-19 pandemic, several hospitals, CATH labs, and ASCs have experienced a rapid decline in the volume of elective cardiology procedures.

Download Free Sample

The drug-coated balloons market by revenue is expected to grow at a CAGR of 15% during the period 2019–2025.

 
The following factors are likely to contribute to the growth of the the drug-coated balloons market during the forecast period:
 
  • Expanding Indications of Drug-Coated Balloons
  • Emergence of Latest Generation DCBs
  • Growth in Target Patient Pool across the Globe
Base Year:         2019
Forecast Year:  2020–2025
 
The study considers the present scenario of the drug-coated balloons devices market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.
 
Prominent Vendors
  • Medtronic
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • BD
  • Koninklijke Philips
  • Boston Scientific
  • B. Braun Melsungen
 Other Prominent Vendors
  • Aachen Resonance
    • Business Overview
    • Product Offerings
  • Acotec Scientific
  • AR Baltic Medical
  • Biosensors International Group
  • BIOTRONIK
  • Cardionovum
  • Concept Medical
  • eucatech
  • ENDOCOR
  • HEXACATH
  • iVascular
  • M.A. Med Alliance
  • Meril Life Sciences
  • Nano Therapeutics
  • QT Vascular
  • RD Global-Invamed
  • STENTYS
  • Surmodics
  • Terumo
  • Urotronic
  • Wellinq

Investigational Companies

  • MICELL TECHNOLOGIES
    • Business Overview
    • Product Offerings
  • Orchestra BioMed

By Indication

  • PAD
  • CAD
  • Others
 By Drug Type
  • Paclitaxel
  • Sirolimus
 By End-user
  • Hospitals
  • Ambulatory Care Settings
  • Freestanding Cath Labs
 By Geography
  •  North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • Turkey
    • South Africa
    • Israel
 
 

1              Research Methodology

2              Research Objectives

3              Research Process

 

4              Scope & Coverage

4.1          Market Definition

4.1.1      Inclusions

4.1.2      Exclusions

4.2          Base Year

4.3          Scope of the Study

4.4          Market Segments

4.4.1      Market Segmentation by Indication

4.4.2      Market Segmentation by Drug Type

4.4.3      Market Segmentation by End-user

4.4.4      Market Segmentation by Geography

 

5              Report Assumptions & Caveats

5.1          Key Caveats

5.2          Currency Conversion

5.3          Market Derivation

 

6              Market at a Glance

 

7              Introduction

7.1          Drug Coated Balloons (DCBS): An Overview

7.1.1      Background

7.1.2      Use of DCBs

 

8              Market Opportunities & Trends

8.1          Increased Application of DCBs to Treat Medical Disorders

8.2          Promising Investigational Drug-Coated Balloons

8.3          Emergence of New Generation DCBs

 

9              Market Growth Enablers

9.1          Global Increase in Target Patient Pool

9.2          Increasing Demand for DCBs Due to Promising Outcomes

9.3          Increased Focus on Generating Abundant Clinical Data

9.4          New Product Approvals/Launches

 

10           Market Restraints

10.1        Presence of Alternative Treatment Procedures

10.2        Stringency in Regulatory Approvals

10.3        Lack of Reimbursement Coverage For DCBs

 

11           Market Landscape

11.1        Market Overview

11.2        COVID-19 Impact on Global Drug-Coated Balloons Market

11.3        Market Size & Forecast

11.3.1    Geographic Insights

11.3.2    Indication Insights

11.3.3    Drug Type

11.3.4    End-User Insights

11.4        Five Forces Analysis

11.4.1    Threat of New Entrants

11.4.2    Bargaining Power of Suppliers

11.4.3    Bargaining Power of Buyers

11.4.4    Threat of Substitutes

11.4.5    Competitive Rivalry

 

12           Drug-coated Balloons Market by Indication

12.1        Snapshot & Growth Engine

12.2        Overview

12.3        PAD

12.3.1    Overview

12.3.2    Size & Forecast

12.4        CAD

12.4.1    Overview

12.4.2    Size & Forecast

12.5        Others

12.5.1    Overview

12.5.2    Size & Forecast

 

13           Drug-coated Balloons Market by Drug Type

13.1        Snapshot & Growth Engine

13.2        Overview

13.3        Paclitaxel

13.3.1    Overview

13.3.2    Size & Forecast

13.4        Sirolimus

13.4.1    Overview

13.4.2    Size & Forecast

 

14           Drug-coated Balloons Market by End-User

14.1        Snapshot & Growth Engine

14.2        Overview

14.3        Hospitals

14.3.1    Overview

14.3.2    Size & Forecast

14.4        Freestanding Cath Labs

14.4.1    Overview

14.4.2    Size & Forecast

14.5        ASCs

14.5.1    Overview

14.5.2    Size & Forecast

 

15           Drug-coated Balloons Market by Geography

15.1        Snapshot & Growth Engine

15.2        Geographic Overview

 

16           North America

16.1        Overview

16.2        Size & Forecast

16.3        Key Countries

16.3.1    US: Drug-coated Balloons Market Size & Forecast

16.3.2    Canada: Size & Forecast

 

17           Europe

17.1        Overview

17.2        Size & Forecast

17.3        Key Countries

17.3.1    Germany: Drug-coated Balloons Market Size & Forecast

17.3.2    France: Size & Forecast

17.3.3    UK: Drug-coated Balloons Market Size & Forecast

17.3.4    Italy: Size & Forecast

17.3.5    Spain: Drug-coated Balloons Market Size & Forecast

 

18           APAC

18.1        Overview

18.2        Size & Forecast

18.4        Key Countries

18.4.1    Japan: Size & Forecast

18.4.2    China: Drug-coated Balloons Market Size & Forecast

18.4.3    Australia: Size & Forecast

18.4.4    South Korea: Drug-coated Balloons Market Size & Forecast

18.4.5    India: Size & Forecast

 

19           Latin America

19.1        Overview

19.2        Size & Forecast

19.3        Key Countries

19.3.1    Brazil: Drug-coated Balloons Market Size & Forecast

19.3.2    Mexico: Size & Forecast

19.3.3    Argentina: Drug-coated Balloons Market Size & Forecast

 

20           Middle East & Africa

20.1        Overview

20.2        Size & Forecast

20.3        Key Countries

20.3.1    Turkey: Drug-coated Balloons Market Size & Forecast

20.3.2    Saudi Arabia: Size & Forecast

20.3.3    Israel: Drug-coated Balloons Market Size & Forecast

20.3.4    South Africa: Size & Forecast

 

21           Competitive Landscape

21.1        Competition Overview

21.2        Market Share Analysis

21.2.1    Medtronic

21.2.2    BD

21.2.3    Koninklijke Philips

21.2.4    Boston Scientific

21.2.5    B. Braun Melsungen

 

22           Key Company Profiles

22.1        Medtronic

22.1.1    Business Overview

22.1.2    Product Offerings

22.1.3    Key Strategies

22.1.4    Key Strengths

22.1.5    Key Opportunities

 

22.2        BD

22.2.1    Business Overview

22.2.2    Product Offerings

22.2.3    Key Strategies

22.2.4    Key Strengths

22.2.5    Key Opportunities

 

22.3        Koninklijke Philips

22.3.1    Business Overview

22.3.2    Product Offerings

22.3.3    Key Strategies

22.3.4    Key Strengths

22.3.5    Key Opportunities

 

22.4        Boston Scientific

22.4.1    Business Overview

22.4.2    Product Offerings

22.4.3    Key Strategies

22.4.4    Key Strengths

22.4.5    Key Opportunities

 

22.5        B. Braun Melsungen

22.5.1    Business Overview

22.5.2    Product Offerings

22.5.3    Key Strategies

22.5.4    Key Strengths

22.5.5    Key Opportunities

 

23           OTHER PROMINENT VENDORS

23.1        Aachen Resonance

23.1.1    Business Overview

23.1.2    Product Offerings

23.2        Acotec Scientific

23.2.1    Business Overview

23.2.2    Product Offerings

23.3        AR Baltic Medical

23.3.1    Business Overview

23.3.2    Product Offerings

23.4        Biosensors International Group

23.4.1    Business Overview

23.4.2    Product Offerings

23.5        Biotronik

23.5.1    Business Overview

23.5.2    Product Offerings

23.6        Cardionovum

23.6.1    Business Overview

23.6.2    Product Offerings

23.7        Concept Medical

23.7.1    Business Overview

23.7.2    Product Offerings

23.8        Eucatech

23.8.1    Business Overview

23.8.2    Product Offerings

23.9        Endocor

23.9.1    Business Overview

23.9.2    Product Offerings

23.1        Hexacath

23.10.1  Business Overview

23.10.2  Product Offerings

23.11     Ivascular

23.11.1  Business Overview

23.11.2  Product Offerings

23.12     M.A. Med Alliance

23.12.1  Business Overview

23.12.2  Product Offerings

23.13     Meril Life Sciences

23.13.1  Business Overview

23.13.2  Product Offerings

23.14     Nano Therapeutics

23.14.1  Business Overview

23.14.2  Product Offerings

23.15     QT Vascular

23.15.1  Business Overview

23.15.2  Product Offerings

23.16     RD Global-Invamed

23.16.1  Business Overview

23.16.2  Product Offerings

23.17     Stentys

23.17.1  Business Overview

23.17.2  Product Offerings

23.18     Surmodics

23.18.1  Business Overview

23.18.2  Product Offerings

23.19     Terumo

23.19.1  Business Overview

23.19.2  Product Offerings

23.2        Urotronic

23.20.1  Business Overview

23.20.2  Product Offerings

23.21     Wellinq

23.21.1  Business Overview

23.21.2  Product Offerings

 

24           Investigational Companies

24.1        Micell Technologies

24.1.1    Business Overview

24.1.2    Investigational Products

24.2        Orchestra Biomed

24.2.1    Business Overview

24.2.2    Investigational Products

 

25           Report Summary

25.1        Key Takeaways

25.2        Strategic Recommendations

 

26           Quantitative Summary

26.1        Indication

26.2        Drug Type

26.3        End-User

26.4        Geography

 

27           Appendix

27.1        Abbreviations

               

Exhibit 1               Segmentation of Global Drug-coated Balloons Market

Exhibit 2               Market Size Calculation Approach 2019

Exhibit 3               Key Application Areas of DCBs

Exhibit 4               Market Dynamics of DCBs

Exhibit 5               Global Drug-coated Balloons Market by Geography 2019 (%)

Exhibit 6               Global Drug-coated Balloons Market by Indication 2019 (%)

Exhibit 7               Impact of Increased Application of DCBs to Treat Medical Disorders

Exhibit 8               Impact of Promising Investigational Drug-coated Balloons

Exhibit 9               Impact of Emergence of New Generation DCBs

Exhibit 10             Impact of Global Increase in Target Patient Pool

Exhibit 11             Impact of Increasing Demand for DCBs due to Promising Outcomes

Exhibit 12             Comparison of Vascular Restenosis in DCBs with Other Devices

Exhibit 13             Comparison of Freedom from Target Lesion Revascularization in DCBs with Other Devices

Exhibit 14             Repeat Procedure Rates for Various PAD Treatment Devices

Exhibit 15             Impact of Increased Focus on Generating Abundant Clinical Data

Exhibit 16             Impact of New Product Approvals/Launches

Exhibit 17             Impact of Presence of Alternative Treatment Procedures

Exhibit 18             Common Alternative Treatment Options to DCBs

Exhibit 19             Impact of Stringency in Regulatory Approvals

Exhibit 20             Major Actions/Sanctions Imposed on Manufacturers by Regulatory Bodies

Exhibit 21             Impact of Lack of Reimbursement Coverage for DCBs

Exhibit 22             COVID-19 Impact on Management of Patients with Acute Coronary Diseases

Exhibit 23             Global Drug-coated Balloons Market 2019–2025 ($ million)

Exhibit 24             Global Drug-coated Balloons Market by Geography

Exhibit 25             Global Drug-coated Balloons Market by Indication

Exhibit 26             Global Drug-coated Balloons Market by Drug Type

Exhibit 27             Global Drug-coated Balloons Market by End-user

Exhibit 28             Five Forces Analysis 2019

Exhibit 29             Incremental Growth by Indication 2019 & 2025

Exhibit 30             The Global Drug-coated Balloons Market by Indication

Exhibit 31             Global Market by Indication: Incremental Growth

Exhibit 32             Global Market by Indication: Absolute Growth

Exhibit 33             Global Drug-coated Balloons Market for PAD: Incremental & Absolute Growth

Exhibit 34             Key Benefits Offered by DCBs Compared to Plain Balloon Angioplasty

Exhibit 35             Global Market for PAD 2019–2025 ($ million)

Exhibit 36             Global Drug-coated Balloons Market for CAD: Incremental & Absolute Growth

Exhibit 37             Global Market for CAD 2019–2025 ($ million)

Exhibit 38             Global Drug-coated Balloons Market for Others: Incremental & Absolute Growth

Exhibit 39             Global Market for Other Indications 2019–2025 ($ million)

Exhibit 40             Incremental Growth by Drug Type 2019 & 2025

Exhibit 41             The Global Drug-coated Balloons Market by Drug Type

Exhibit 42             Global Market by Product: Incremental Growth

Exhibit 43             Global Market by Product: Absolute Growth

Exhibit 44             Global Paclitaxel-coated Balloons Market: Incremental & Absolute Growth

Exhibit 45             Global Filter Paclitaxel-coated Balloons Market 2019–2025 ($ million)

Exhibit 46             Global Sirolimus-coated Balloons Market: Incremental & Absolute Growth

Exhibit 47             Global Filter Sirolimus-coated Balloons Market 2019–2025 ($ million)

Exhibit 48             Incremental Growth by End-user 2019 & 2025

Exhibit 49             The Global Drug-coated Balloons Market by End-user

Exhibit 50             Global Market by End-user: Incremental Growth

Exhibit 51             Global market by End-user: Absolute Growth

Exhibit 52             Global Market by Hospitals: Incremental & Absolute Growth

Exhibit 53             Global Market by Hospitals 2019–2025 ($ million)

Exhibit 54             Global Market by Freestanding CATH Labs: Incremental & Absolute Growth

Exhibit 55             Global Market by Freestanding CATH Labs 2019–2025 ($ million)

Exhibit 56             Global Market by ASCs: Incremental & Absolute Growth

Exhibit 57             Global Market by ASCs 2019–2025 ($ million)

Exhibit 58             Incremental Growth by Geography 2019 & 2025

Exhibit 59             The Global Drug-coated Balloons Market by Geography

Exhibit 60             Global Market by Geography 2019: Key Countries ($ million)

Exhibit 61             Global Market by Geography: Incremental Growth

Exhibit 62             Global Market by Geography: Absolute Growth

Exhibit 63             Global Drug-coated Balloons Market in North America 2019

Exhibit 64             North America Market: Absolute & Incremental Growth

Exhibit 65             Market in North America 2019–2025 ($ million)

Exhibit 66             Incremental Growth in North America 2019 & 2025

Exhibit 67             Market in US 2019–2025 ($ million)

Exhibit 68             Market in Canada 2019–2025 ($ million)

Exhibit 69             Europe Drug-coated Balloons Market: Key Countries 2019

Exhibit 70             Market in Europe: Incremental & Absolute Growth

Exhibit 71             Number of PCI Procedures Performed with DCBs across Europe in 2016 (per million people)

Exhibit 72             Market in Europe 2019–2025 ($ million)

Exhibit 73             Incremental Growth in Europe 2019 & 2025

Exhibit 74             Market in Germany 2019–2025 ($ million)

Exhibit 75             Market in France 2019–2025 ($ million)

Exhibit 76             Market in UK 2019–2025 ($ million)

Exhibit 77             Market in Italy 2019–2025 ($ million)

Exhibit 78             Market in Spain 2019–2025 ($ million)

Exhibit 79             APAC Drug-coated Balloons Market in 2019

Exhibit 80             APAC Market: Incremental & Absolute Growth

Exhibit 81             Market in APAC 2019–2025 ($ million)

Exhibit 82             Population Demographics in APAC

Exhibit 83             Health Access & Quality Index Score for Key APAC Countries 2016

Exhibit 84             Incremental Growth in APAC 2019 & 2025

Exhibit 85             Market in Japan 2019–2025 ($ million)

Exhibit 86             Market in China 2019–2025 ($ million)

Exhibit 87             Market in Australia 2019–2025 ($ million)

Exhibit 88             Market in South Korea 2019–2025 ($ million)

Exhibit 89             Market in India 2019–2025 ($ million)

Exhibit 90             Latin America Drug-coated Balloons Market 2019

Exhibit 91             Market in Latin America: Incremental & Absolute Growth

Exhibit 92             Market in Latin America 2019–2025 ($ million)

Exhibit 93             Incremental Growth in Latin America 2019 & 2025

Exhibit 94             Market in Brazil 2019–2025 ($ million)

Exhibit 95             Market in Mexico 2019–2025 ($ million)

Exhibit 96             Market in Argentina 2019–2025 ($ million)

Exhibit 97             Middle East & Africa Drug-coated Balloons Market in 2019

Exhibit 98             Middle East & Africa Market: Incremental & Absolute Growth

Exhibit 99             Market in Middle East & Africa 2019–2025 ($ million)

Exhibit 100          Incremental Growth in Middle East & Africa 2019 & 2025

Exhibit 101          Market in Turkey 2019–2025 ($ million)

Exhibit 102          Market in Saudi Arabia 2019–2025 ($ million)

Exhibit 103          Market in Israel 2019–2025 ($ million)

Exhibit 104          Market in South Africa 2019–2025 ($ million)

Exhibit 105          Market Share (2019)

Exhibit 106          Medtronic: R&D Expenditure 2017−2019 ($ million)

Exhibit 107          Medtronic: Revenue by Segment 2018 & 2019 ($ million)

Exhibit 108          Medtronic: Revenue by Geography 2019 (%)

Exhibit 109          BD: R&D Expenditure 2017−2019 ($ million)

Exhibit 110          BD: Revenue by Business Segments 2018 & 2019 ($ million)

Exhibit 111          BD: Revenue by Geography 2019 (%)

Exhibit 112          Koninklijke Philips: R&D Expenditure 2017−2019 ($ million)

Exhibit 113          Koninklijke Philips: Revenue by Segments 2018 & 2019 ($ million)

Exhibit 114          Koninklijke Philips: Revenue by Geography 2019 (%)

Exhibit 115          Boston Scientific: R&D Expenditure 2017−2019 ($ million)

Exhibit 116          Boston Scientific: Revenue by Business Segments 2018 & 2019 ($ million)

Exhibit 117          Boston Scientific: Revenue by Geography 2019 (%)

Exhibit 118          B. Braun Melsungen: R&D Spend 2017−2019 ($ million)

Exhibit 119          B. Braun Melsungen: Revenue by Segment 2018 & 2019 ($ million)

Exhibit 120          Braun Melsungen: Revenue by Geography 2019 (%)

               

LIST OF TABLES 

Table 1                  Key Caveats

Table 2                  Currency Conversion 2013−2019

Table 3                  Extended Indications for DCBs

Table 4                  Major Pipeline DCBs

Table 5                  Major Latest-generation DCBs Available in Market

Table 6                  Global Drug-coated Balloons Market: Major Clinical Trials Conducted on DCBs by Various Vendors

Table 7                  Product Approvals/Launches in Global Drug-coated Balloons Market 2016−2020

Table 8                  Significant Players Offering DCBs for PAD Indications

Table 9                  Significant Players Offering DCBs for CAD Intervention

Table 10               Significant Players Offering DCBs for Others

Table 11               Key Paclitaxel-coated Balloons Offered by Significant Players

Table 12               Key Sirolimus-coated Balloons Offered by Significant Players

Table 13               Provincial Reimbursement Policy in China

Table 14               Competitive Structure of the Global Drug-coated Balloons Market

Table 15               Global Drug-coated Balloons Market: Vendors Ranking 2019

Table 16               Medtronic: Major Product Offerings

Table 17               BD: Major Product Offerings

Table 18               Koninklijke Philips: Major Product Offerings

Table 19               Boston Scientific: Major Product Offerings

Table 20               B. Braun Melsungen: Major Product Offerings

Table 21               Aachen Resonance: Major Product Offerings

Table 22               Acotec Scientific: Major Product Offerings

Table 23               AR Baltic Medical: Major Product Offerings

Table 24               Biosensors International Group: Major Product Offerings

Table 25               BIOTRONIK: Major Product Offerings

Table 26               Cardionovum: Major Product Offerings

Table 27               Concept Medical: Major Product Offerings

Table 28               eucatech: Major Product Offerings

Table 29               ENDOCOR: Major Product Offerings

Table 30               HEXACATH: Major Product Offerings

Table 31               iVascular: Major Product Offerings

Table 32               M.A. Med Alliance: Major Product Offerings

Table 33               Meril Life Sciences: Major Product Offerings

Table 34               Nano Therapeutics: Major Product Offerings

Table 35               QT Vascular: Major Product Offerings

Table 36               RD Global-Invamed: Major Product Offerings

Table 37               STENTYS: Major Product Offerings

Table 38               Surmodics: Major Product Offerings

Table 39               Terumo: Major Product Offerings

Table 40               Urotronic: Major Product Offerings

Table 41               Wellinq: Major Product Offerings

Table 42               MICELL TECHNOLOGIES: Investigational Product

Table 43               Orchestra BioMed: Major Investigational Products

Table 44               Global Market by Indication 2019−2025 ($ million)

Table 45               Global Market by Indication 2019−2025 (%)

Table 46               Global Market by Drug Type 2019−2025 ($ million)

Table 47               Global Market by Drug Type 2019−2025 (%)

Table 48               Global Market by End-user 2019−2025 ($ million)

Table 49               Global Market by End-user 2019−2025 (%)

Table 50               Global Market by Geography 2019−2025 ($ million)

Table 51               Global Market by Geography 2019−2025 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date